2017 Press Releases

2017 Press Releases

2017 | 2016 | 2015
  • Jun 07, 2017 

    Novavax RSV F Vaccine Phase 2 Clinical Trial Data in Women of Child Bearing Age Published in Vaccine - 

    Trial demonstrated a reduction of RSV infection in vaccinated women of greater than 50%, suggesting potential benefits to the mother, pregnancy outcomes and her infant GAITHERSBURG, Md., June 7, 2017 /PRNewswire/ -- Novavax, Inc., (Nasdaq:NVAX) today announced that data from the second of two Phase 2 trials of its RSV F protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in women of child bearing age have been published in the journal Vaccine (the data contained in this... More >>

  • May 11, 2017 

    Novavax Announces the Promotion of Dr. James F. Cummings to Vice President, Clinical Development and Translational Medicine - 

    GAITHERSBURG, Md., May 11, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), today announced that Dr. James F. Cummings has been promoted to Vice President, Clinical Development and Translational Medicine. Dr. Cummings joined Novavax as Senior Director of Clinical Development in September 2015, with a specific focus on advancing Novavax’ programs within emerging infectious disease.  Previously, Dr. Cummings served as the Director for Global Emerging Infections Surveillance and Response Sys... More >>

  • May 08, 2017 

    Novavax Reports First Quarter 2017 Financial Results - 

    GAITHERSBURG, Md., May 08, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced its financial results for the first quarter ended March 31, 2017. First Quarter Achievements: Enrollment continued during the second global season in the RSV Phase 3 Prepare™ clinical trial for infants via maternal immunization. Enrollment in the first quarter of 2017 transitioned from the northern hemisphere to southern hemisphere sites in Argentina, Australia, Chile, New Zealand and South... More >>

  • May 01, 2017 

    Novavax to Host Conference Call to Discuss First Quarter 2017 Financial Results on May 8, 2017 - 

    GAITHERSBURG, Md., May 01, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2017 financial and operating results following the close of U.S. financial markets on Monday, May 8, 2017. Conference call details are as follows: Date:      Monday, May 8, 2017 Time:    4:30 p.m. U.S. Eastern Time (ET) Dial-in number:   (877) 212-6076 (Domestic) or (707) 287-9331 (International... More >>

  • Feb 27, 2017 

    Novavax Reports Fourth Quarter and Year-End 2016 Financial Results - 

    GAITHERSBURG, Md., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced its financial results for the fourth quarter and twelve months ended December 31, 2016. Recent and Fourth Quarter Achievements: Continued execution of the global Phase 3 Prepare™ clinical trial to prevent RSV in infants via maternal immunization. Prepare is a randomized, observer-blinded, placebo-controlled trial, conducted at multiple international sites. The primary objective is to deter... More >>

  • Feb 20, 2017 

    Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2016 Financial Results on February 27, 2017 - 

    GAITHERSBURG, Md., Feb. 20, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its fourth quarter and full year 2016 financial and operating results following the close of U.S. financial markets on Monday, February 27, 2017. Conference call details are as follows: Date:   Monday, February 27, 2017 Time:   4:30 p.m. U.S. Eastern Time (ET) Dial-in number:   (877) 212-6076 (Domestic) or (707) 287-... More >>

  • Jan 19, 2017 

    Novavax Initiates Phase 2 Safety and Immunogenicity Trial of the RSV F Vaccine in Older Adults - 

    GAITHERSBURG, Md., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced the initiation of a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine) in older adults (60 years of age and older). The objective of the trial is to assess safety and immunogenicity to one and two dose regimens of the RSV F Vaccine, with and without aluminum phosphate or Novavax’ proprietary Matrix-M™ adjuvant, in older adults. The ... More >>

  • Jan 05, 2017 

    Novavax to Present at the 35th Annual J.P. Morgan Healthcare Conference - 

    GAITHERSBURG, Md., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that management will present at the 35th Annual J.P. Morgan Healthcare Conference. Presentation details are as follows: Date: Thursday, January 12, 2017 Time: 9:30 am U.S. Pacific Time Location: California East room, Westin St. Francis Hotel, San Francisco Live webcast: novavax.com, “Investors”/ “Events” The webcast and replay of the presentation will also be accessible under the “Investors... More >>